newsfilter
← Latest News
GlobeNewswire·

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

– Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress – – On track to submit global regulatory